{"pmid":32324595,"title":"The laboratory tests and host immunity of COVID-19 patients with different severity of illness.","text":["The laboratory tests and host immunity of COVID-19 patients with different severity of illness.","BACKGROUND: The Coronavirus Disease-2019 (COVID-19), infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a severe outbreak in China. The host immunity of COVID-19 patients is unknown. METHODS: The routine laboratory tests and host immunity in COVID-19 patients with different severity of illness were compared after patient admission. RESULTS: A total of 65 SARS-CoV-2-positive patients were classified as mild (n=30), severe (n=20), and extremely severe (n=15) illness. Many routine laboratory tests such as ferritin, lactate dehydrogenase and D-dimer were increased in severe and extremely severe patients. The absolute numbers of CD4+ T cells, CD8+ T cells and B cells were all gradually decreased with increased severity of illness. The activation markers such as HLA-DR and CD45RO expressed on CD4+ and CD8+ T cells were increased in severe and extremely severe patients compared with mild patients. The co-stimulatory molecule CD28 had opposite results. The percentage of natural regulatory T cells was decreased in extremely severe patients. The percentage of IFN-gamma producing CD8+ T cells was increased in both severe and extremely severe patients compared with mild patients. The percentage of IFN-gamma producing CD4+ T cells was increased in extremely severe patients. The IL-2R, IL-6, and IL-10 were all increased in extremely severe patients. The activation of DC and B cells was decreased in extremely severe patients. CONCLUSIONS: The number and function of T cells are inconsistent in COVID-19 patients. The hyperfunction of CD4+ and CD8+ T cells is associated with the pathogenesis of extremely severe SARS-CoV-2 infection.","JCI Insight","Wang, Feng","Hou, Hongyan","Luo, Ying","Tang, Guoxing","Wu, Shiji","Huang, Min","Liu, Weiyong","Zhu, Yaowu","Lin, Qun","Mao, Liyan","Fang, Minghao","Zhang, Huilan","Sun, Ziyong","32324595"],"abstract":["BACKGROUND: The Coronavirus Disease-2019 (COVID-19), infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a severe outbreak in China. The host immunity of COVID-19 patients is unknown. METHODS: The routine laboratory tests and host immunity in COVID-19 patients with different severity of illness were compared after patient admission. RESULTS: A total of 65 SARS-CoV-2-positive patients were classified as mild (n=30), severe (n=20), and extremely severe (n=15) illness. Many routine laboratory tests such as ferritin, lactate dehydrogenase and D-dimer were increased in severe and extremely severe patients. The absolute numbers of CD4+ T cells, CD8+ T cells and B cells were all gradually decreased with increased severity of illness. The activation markers such as HLA-DR and CD45RO expressed on CD4+ and CD8+ T cells were increased in severe and extremely severe patients compared with mild patients. The co-stimulatory molecule CD28 had opposite results. The percentage of natural regulatory T cells was decreased in extremely severe patients. The percentage of IFN-gamma producing CD8+ T cells was increased in both severe and extremely severe patients compared with mild patients. The percentage of IFN-gamma producing CD4+ T cells was increased in extremely severe patients. The IL-2R, IL-6, and IL-10 were all increased in extremely severe patients. The activation of DC and B cells was decreased in extremely severe patients. CONCLUSIONS: The number and function of T cells are inconsistent in COVID-19 patients. The hyperfunction of CD4+ and CD8+ T cells is associated with the pathogenesis of extremely severe SARS-CoV-2 infection."],"journal":"JCI Insight","authors":["Wang, Feng","Hou, Hongyan","Luo, Ying","Tang, Guoxing","Wu, Shiji","Huang, Min","Liu, Weiyong","Zhu, Yaowu","Lin, Qun","Mao, Liyan","Fang, Minghao","Zhang, Huilan","Sun, Ziyong"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32324595","week":"202017|Apr 20 - Apr 26","doi":"10.1172/jci.insight.137799","keywords":["adaptive immunity","cellular immune response","immunology","infectious disease","innate immunity"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664895932700819456,"score":8.518259,"similar":[{"pmid":32217835,"title":"Clinical and immunological features of severe and moderate coronavirus disease 2019.","text":["Clinical and immunological features of severe and moderate coronavirus disease 2019.","BACKGROUNDSince December 2019, an outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, and is now becoming a global threat. We aimed to delineate and compare the immunological features of severe and moderate COVID-19.METHODSIn this retrospective study, the clinical and immunological characteristics of 21 patients (17 male and 4 female) with COVID-19 were analyzed. These patients were classified as severe (11 cases) and moderate (10 cases) according to the guidelines released by the National Health Commission of China.RESULTSThe median age of severe and moderate cases was 61.0 and 52.0 years, respectively. Common clinical manifestations included fever, cough, and fatigue. Compared with moderate cases, severe cases more frequently had dyspnea, lymphopenia, and hypoalbuminemia, with higher levels of alanine aminotransferase, lactate dehydrogenase, C-reactive protein, ferritin, and D-dimer as well as markedly higher levels of IL-2R, IL-6, IL-10, and TNF-alpha. Absolute numbers of T lymphocytes, CD4+ T cells, and CD8+ T cells decreased in nearly all the patients, and were markedly lower in severe cases (294.0, 177.5, and 89.0 x 106/L, respectively) than moderate cases (640.5, 381.5, and 254.0 x 106/L, respectively). The expression of IFN-gamma by CD4+ T cells tended to be lower in severe cases (14.1%) than in moderate cases (22.8%).CONCLUSIONThe SARS-CoV-2 infection may affect primarily T lymphocytes, particularly CD4+ and CD8+ T cells, resulting in a decrease in numbers as well as IFN-gamma production by CD4+ T cells. These potential immunological markers may be of importance because of their correlation with disease severity in COVID-19.TRIAL REGISTRATIONThis is a retrospective observational study without a trial registration number.FUNDINGThis work is funded by grants from Tongji Hospital for the Pilot Scheme Project, and partly supported by the Chinese National Thirteenth Five Years Project in Science and Technology for Infectious Disease (2017ZX10202201).","J Clin Invest","Chen, Guang","Wu, Di","Guo, Wei","Cao, Yong","Huang, Da","Wang, Hongwu","Wang, Tao","Zhang, Xiaoyun","Chen, Huilong","Yu, Haijing","Zhang, Xiaoping","Zhang, Minxia","Wu, Shiji","Song, Jianxin","Chen, Tao","Han, Meifang","Li, Shusheng","Luo, Xiaoping","Zhao, Jianping","Ning, Qin","32217835"],"abstract":["BACKGROUNDSince December 2019, an outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, and is now becoming a global threat. We aimed to delineate and compare the immunological features of severe and moderate COVID-19.METHODSIn this retrospective study, the clinical and immunological characteristics of 21 patients (17 male and 4 female) with COVID-19 were analyzed. These patients were classified as severe (11 cases) and moderate (10 cases) according to the guidelines released by the National Health Commission of China.RESULTSThe median age of severe and moderate cases was 61.0 and 52.0 years, respectively. Common clinical manifestations included fever, cough, and fatigue. Compared with moderate cases, severe cases more frequently had dyspnea, lymphopenia, and hypoalbuminemia, with higher levels of alanine aminotransferase, lactate dehydrogenase, C-reactive protein, ferritin, and D-dimer as well as markedly higher levels of IL-2R, IL-6, IL-10, and TNF-alpha. Absolute numbers of T lymphocytes, CD4+ T cells, and CD8+ T cells decreased in nearly all the patients, and were markedly lower in severe cases (294.0, 177.5, and 89.0 x 106/L, respectively) than moderate cases (640.5, 381.5, and 254.0 x 106/L, respectively). The expression of IFN-gamma by CD4+ T cells tended to be lower in severe cases (14.1%) than in moderate cases (22.8%).CONCLUSIONThe SARS-CoV-2 infection may affect primarily T lymphocytes, particularly CD4+ and CD8+ T cells, resulting in a decrease in numbers as well as IFN-gamma production by CD4+ T cells. These potential immunological markers may be of importance because of their correlation with disease severity in COVID-19.TRIAL REGISTRATIONThis is a retrospective observational study without a trial registration number.FUNDINGThis work is funded by grants from Tongji Hospital for the Pilot Scheme Project, and partly supported by the Chinese National Thirteenth Five Years Project in Science and Technology for Infectious Disease (2017ZX10202201)."],"journal":"J Clin Invest","authors":["Chen, Guang","Wu, Di","Guo, Wei","Cao, Yong","Huang, Da","Wang, Hongwu","Wang, Tao","Zhang, Xiaoyun","Chen, Huilong","Yu, Haijing","Zhang, Xiaoping","Zhang, Minxia","Wu, Shiji","Song, Jianxin","Chen, Tao","Han, Meifang","Li, Shusheng","Luo, Xiaoping","Zhao, Jianping","Ning, Qin"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32217835","week":"202013|Mar 23 - Mar 29","doi":"10.1172/JCI137244","keywords":["cytokines","immunology","infectious disease","respiration","t cells"],"source":"PubMed","topics":["Diagnosis","Mechanism"],"weight":1,"locations":["Wuhan","ferritin"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664638742960275456,"score":527.7021},{"pmid":32325421,"title":"Increased expression of CD8 marker on T-cells in COVID-19 patients.","text":["Increased expression of CD8 marker on T-cells in COVID-19 patients.","BACKGROUND: Cell-mediated immunity including T-cells (T helper and cytotoxic) plays an essential role in efficient antiviral responses against coronavirus disease-2019 (COVID-19). Therefore, in this study, we evaluated the ratio and expression of CD4 and CD8 markers in COVID-19 patients to clarify the immune characterizations of CD4 and CD8 T-cells in COVID-19 patients. METHODS: Peripheral blood samples of 25 COVID-19 patients and 25 normal individuals with similar age and sex as the control group were collected. White blood cells, platelets, and lymphocytes were counted and CD4 and CD8 T lymphocytes were evaluated by flow cytometry. RESULTS: The number of white blood cells, lymphocytes, and platelets were reduced significantly in COVID-19 patients (P < 0.05). The difference in CD4:CD8 ratio, CD4 T-cell frequency, CD8 T-cell frequency, and CD4 mean fluorescence intensity (MFI) was not significant between COVID-19 patients and healthy individuals (P > 0.05); however, the CD8 MFI increased significantly in COVID-19 infected patients (P < 0.05). CONCLUSION: Although, there is no significant difference in the ratio of CD4 to CD8 between two groups, the expression level of CD8 in COVID-19 patients was significantly higher than the normal individuals. This result suggested that the cellular immune responses triggered by COVID-19 infection were developed through overexpression of CD8 and hyperactivation of cytotoxic T lymphocytes.","Blood Cells Mol Dis","Ganji, Ali","Farahani, Iman","Khansarinejad, Behzad","Ghazavi, Ali","Mosayebi, Ghasem","32325421"],"abstract":["BACKGROUND: Cell-mediated immunity including T-cells (T helper and cytotoxic) plays an essential role in efficient antiviral responses against coronavirus disease-2019 (COVID-19). Therefore, in this study, we evaluated the ratio and expression of CD4 and CD8 markers in COVID-19 patients to clarify the immune characterizations of CD4 and CD8 T-cells in COVID-19 patients. METHODS: Peripheral blood samples of 25 COVID-19 patients and 25 normal individuals with similar age and sex as the control group were collected. White blood cells, platelets, and lymphocytes were counted and CD4 and CD8 T lymphocytes were evaluated by flow cytometry. RESULTS: The number of white blood cells, lymphocytes, and platelets were reduced significantly in COVID-19 patients (P < 0.05). The difference in CD4:CD8 ratio, CD4 T-cell frequency, CD8 T-cell frequency, and CD4 mean fluorescence intensity (MFI) was not significant between COVID-19 patients and healthy individuals (P > 0.05); however, the CD8 MFI increased significantly in COVID-19 infected patients (P < 0.05). CONCLUSION: Although, there is no significant difference in the ratio of CD4 to CD8 between two groups, the expression level of CD8 in COVID-19 patients was significantly higher than the normal individuals. This result suggested that the cellular immune responses triggered by COVID-19 infection were developed through overexpression of CD8 and hyperactivation of cytotoxic T lymphocytes."],"journal":"Blood Cells Mol Dis","authors":["Ganji, Ali","Farahani, Iman","Khansarinejad, Behzad","Ghazavi, Ali","Mosayebi, Ghasem"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32325421","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.bcmd.2020.102437","keywords":["2019-ncov","cd4 lymphocyte","cd8 lymphocyte","covid-19","coronavirus"],"source":"PubMed","topics":["Mechanism"],"weight":1,"_version_":1664895932802531328,"score":409.08902},{"pmid":32227123,"title":"Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia.","text":["Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia.","BACKGROUND: Since December 2019, novel coronavirus (SARS-CoV-2)-infected pneumonia (COVID-19) occurred in Wuhan, and rapidly spread throughout China. We aimed to clarify the characteristics and clinical significance of peripheral lymphocyte subset alteration in COVID-19. METHODS: The levels of peripheral lymphocyte subsets were measured by flow cytometry in 60 hospitalized COVID-19 patients before and after treatment, and their association with clinical characteristics and treatment efficacy was analyzed. RESULTS: Total lymphocytes, CD4+ T cells, CD8+ T cells, B cells and natural killer (NK) cells decreased in COVID-19 patients, and severe cases had a lower level than mild cases. The subsets showed a significant association with the inflammatory status in COVID-19, especially CD8+ T cells and CD4+/CD8+ ratio. After treatment, 37 patients (67%) reached clinical response, with an increase of CD8+ T cells and B cells. No significant change of any subset was detected in non-response cases. In multivariate analysis, post-treatment decrease of CD8+ T cells and B cells and increase of CD4+/CD8+ ratio were indicated as independent predictors for poor efficacy. CONCLUSIONS: Peripheral lymphocyte subset alteration was associated with the clinical characteristics and treatment efficacy of COVID-19. CD8+ T cells tended to be an independent predictor for COVID-19 severity and treatment efficacy.","J Infect Dis","Wang, Fan","Nie, Jiayan","Wang, Haizhou","Zhao, Qiu","Xiong, Yong","Deng, Liping","Song, Shihui","Ma, Zhiyong","Mo, Pingzheng","Zhang, Yongxi","32227123"],"abstract":["BACKGROUND: Since December 2019, novel coronavirus (SARS-CoV-2)-infected pneumonia (COVID-19) occurred in Wuhan, and rapidly spread throughout China. We aimed to clarify the characteristics and clinical significance of peripheral lymphocyte subset alteration in COVID-19. METHODS: The levels of peripheral lymphocyte subsets were measured by flow cytometry in 60 hospitalized COVID-19 patients before and after treatment, and their association with clinical characteristics and treatment efficacy was analyzed. RESULTS: Total lymphocytes, CD4+ T cells, CD8+ T cells, B cells and natural killer (NK) cells decreased in COVID-19 patients, and severe cases had a lower level than mild cases. The subsets showed a significant association with the inflammatory status in COVID-19, especially CD8+ T cells and CD4+/CD8+ ratio. After treatment, 37 patients (67%) reached clinical response, with an increase of CD8+ T cells and B cells. No significant change of any subset was detected in non-response cases. In multivariate analysis, post-treatment decrease of CD8+ T cells and B cells and increase of CD4+/CD8+ ratio were indicated as independent predictors for poor efficacy. CONCLUSIONS: Peripheral lymphocyte subset alteration was associated with the clinical characteristics and treatment efficacy of COVID-19. CD8+ T cells tended to be an independent predictor for COVID-19 severity and treatment efficacy."],"journal":"J Infect Dis","authors":["Wang, Fan","Nie, Jiayan","Wang, Haizhou","Zhao, Qiu","Xiong, Yong","Deng, Liping","Song, Shihui","Ma, Zhiyong","Mo, Pingzheng","Zhang, Yongxi"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32227123","week":"202014|Mar 30 - Apr 05","doi":"10.1093/infdis/jiaa150","keywords":["covid-19","lymphocyte subset","pneumonia"],"source":"PubMed","topics":["Diagnosis","Treatment"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664640912730357760,"score":381.02673},{"pmid":32315725,"title":"Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan, China.","text":["Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan, China.","IMPORTANCE: An ongoing outbreak of COVID-19 has exhibited significant threats around the world. We found a significant decrease of T lymphocyte subsets and an increase of inflammatory cytokines of hospitalized patients with COVID-19 in clinical practice. METHODS: We conducted a retrospective, single-center observational study of in-hospital adult patients with confirmed COVID-19 in Hubei Provincial Hospital of traditional Chinese and Western medicine (Wuhan, China) by Mar 1, 2020. Demographic, clinical, laboratory information, especially T lymphocyte subsets and inflammatory cytokines were reported. For patients who died or discharge from hospital, the associations of T lymphocyte subsets on admission were evaluated by univariate logistic regression with odds ratios (ORs) and 95% confidence intervals (CIs), warning values to predict in-hospital death were assessed by Receiver Operator Characteristic (ROC) curves. RESULTS: A total of 187 patients were enrolled in our study from Dec 26, 2019 to Mar 1, 2020, of whom 145 were survivors (discharge= 117) or non-survivors (in-hospital death=28). All patients exhibited a significant drop of T lymphocyte subsets counts with remarkably increasing concentrations of SAA, CRP, IL-6, and IL-10 compared to normal values. The median concentrations of SAA and CRP in critically-ill patients were nearly 4- and 10-fold than those of mild-ill patients, respectively. As the severity of COVID-19 getting worse, the counts of T lymphocyte drop lower.28 patients died in hospital, the median lymphocyte, CD3+ T-cell, CD4+ T-cell, CD8+ T-cell and B-cell were significantly lower than other patients. Lower counts (/uL) of T lymphocyte subsets lymphocyte (<500), CD3+T-cell (<200), CD4+ T-cell (<100), CD8+ T-cell (<100) and B-cell (<50) were associated with higher risks of in-hospital death of CIVID-19. The warning values to predict in-hospital death of lymphocyte, CD3+ T-cell, CD4+ T-cell, CD8+ T-cell, and B-cell were 559, 235, 104, 85 and 82, respectively. CONCLUSION: We find a significant decrease of T lymphocyte subset is positively correlated with in-hospital death and severity of illness. The decreased levels of T lymphocyte subsets reported in our study were similar with SARS but not common among other virus infection, which may be possible biomarkers for early diagnosis of COVID-19. Our findings may shed light on early warning of high risks of mortality and help early intervention and treatment of COVID-19.","J Infect","Xu, Bo","Fan, Cun-Yu","Wang, An-Lu","Zou, Yi-Long","Yu, Yi-Han","He, Cong","Xia, Wen-Guang","Zhang, Ji-Xian","Miao, Qing","32315725"],"abstract":["IMPORTANCE: An ongoing outbreak of COVID-19 has exhibited significant threats around the world. We found a significant decrease of T lymphocyte subsets and an increase of inflammatory cytokines of hospitalized patients with COVID-19 in clinical practice. METHODS: We conducted a retrospective, single-center observational study of in-hospital adult patients with confirmed COVID-19 in Hubei Provincial Hospital of traditional Chinese and Western medicine (Wuhan, China) by Mar 1, 2020. Demographic, clinical, laboratory information, especially T lymphocyte subsets and inflammatory cytokines were reported. For patients who died or discharge from hospital, the associations of T lymphocyte subsets on admission were evaluated by univariate logistic regression with odds ratios (ORs) and 95% confidence intervals (CIs), warning values to predict in-hospital death were assessed by Receiver Operator Characteristic (ROC) curves. RESULTS: A total of 187 patients were enrolled in our study from Dec 26, 2019 to Mar 1, 2020, of whom 145 were survivors (discharge= 117) or non-survivors (in-hospital death=28). All patients exhibited a significant drop of T lymphocyte subsets counts with remarkably increasing concentrations of SAA, CRP, IL-6, and IL-10 compared to normal values. The median concentrations of SAA and CRP in critically-ill patients were nearly 4- and 10-fold than those of mild-ill patients, respectively. As the severity of COVID-19 getting worse, the counts of T lymphocyte drop lower.28 patients died in hospital, the median lymphocyte, CD3+ T-cell, CD4+ T-cell, CD8+ T-cell and B-cell were significantly lower than other patients. Lower counts (/uL) of T lymphocyte subsets lymphocyte (<500), CD3+T-cell (<200), CD4+ T-cell (<100), CD8+ T-cell (<100) and B-cell (<50) were associated with higher risks of in-hospital death of CIVID-19. The warning values to predict in-hospital death of lymphocyte, CD3+ T-cell, CD4+ T-cell, CD8+ T-cell, and B-cell were 559, 235, 104, 85 and 82, respectively. CONCLUSION: We find a significant decrease of T lymphocyte subset is positively correlated with in-hospital death and severity of illness. The decreased levels of T lymphocyte subsets reported in our study were similar with SARS but not common among other virus infection, which may be possible biomarkers for early diagnosis of COVID-19. Our findings may shed light on early warning of high risks of mortality and help early intervention and treatment of COVID-19."],"journal":"J Infect","authors":["Xu, Bo","Fan, Cun-Yu","Wang, An-Lu","Zou, Yi-Long","Yu, Yi-Han","He, Cong","Xia, Wen-Guang","Zhang, Ji-Xian","Miao, Qing"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32315725","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jinf.2020.04.012","keywords":["covid-19","immunity","retrospective study","t cell subsets"],"source":"PubMed","topics":["Treatment","Diagnosis"],"weight":1,"locations":["Chinese","Western","Wuhan","China","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664714520169283584,"score":371.7214},{"pmid":32320677,"title":"Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure.","text":["Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure.","Proper management of COVID-19 mandates better understanding of disease pathogenesis. The sudden clinical deterioration 7-8 days after initial symptom onset suggests that severe respiratory failure (SRF) in COVID-19 is driven by a unique pattern of immune dysfunction. We studied immune responses of 54 COVID-19 patients, 28 of whom had SRF. All patients with SRF displayed either macrophage activation syndrome (MAS) or very low human leukocyte antigen D related (HLA-DR) expression accompanied by profound depletion of CD4 lymphocytes, CD19 lymphocytes, and natural killer (NK) cells. Tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) production by circulating monocytes was sustained, a pattern distinct from bacterial sepsis or influenza. SARS-CoV-2 patient plasma inhibited HLA-DR expression, and this was partially restored by the IL-6 blocker Tocilizumab; off-label Tocilizumab treatment of patients was accompanied by increase in circulating lymphocytes. Thus, the unique pattern of immune dysregulation in severe COVID-19 is characterized by IL-6-mediated low HLA-DR expression and lymphopenia, associated with sustained cytokine production and hyper-inflammation.","Cell Host Microbe","Giamarellos-Bourboulis, Evangelos J","Netea, Mihai G","Rovina, Nikoletta","Akinosoglou, Karolina","Antoniadou, Anastasia","Antonakos, Nikolaos","Damoraki, Georgia","Gkavogianni, Theologia","Adami, Maria-Evangelia","Katsaounou, Paraskevi","Ntaganou, Maria","Kyriakopoulou, Magdalini","Dimopoulos, George","Koutsodimitropoulos, Ioannis","Velissaris, Dimitrios","Koufargyris, Panagiotis","Karageorgos, Athanassios","Katrini, Konstantina","Lekakis, Vasileios","Lupse, Mihaela","Kotsaki, Antigone","Renieris, George","Theodoulou, Danai","Panou, Vassiliki","Koukaki, Evangelia","Koulouris, Nikolaos","Gogos, Charalambos","Koutsoukou, Antonia","32320677"],"abstract":["Proper management of COVID-19 mandates better understanding of disease pathogenesis. The sudden clinical deterioration 7-8 days after initial symptom onset suggests that severe respiratory failure (SRF) in COVID-19 is driven by a unique pattern of immune dysfunction. We studied immune responses of 54 COVID-19 patients, 28 of whom had SRF. All patients with SRF displayed either macrophage activation syndrome (MAS) or very low human leukocyte antigen D related (HLA-DR) expression accompanied by profound depletion of CD4 lymphocytes, CD19 lymphocytes, and natural killer (NK) cells. Tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) production by circulating monocytes was sustained, a pattern distinct from bacterial sepsis or influenza. SARS-CoV-2 patient plasma inhibited HLA-DR expression, and this was partially restored by the IL-6 blocker Tocilizumab; off-label Tocilizumab treatment of patients was accompanied by increase in circulating lymphocytes. Thus, the unique pattern of immune dysregulation in severe COVID-19 is characterized by IL-6-mediated low HLA-DR expression and lymphopenia, associated with sustained cytokine production and hyper-inflammation."],"journal":"Cell Host Microbe","authors":["Giamarellos-Bourboulis, Evangelos J","Netea, Mihai G","Rovina, Nikoletta","Akinosoglou, Karolina","Antoniadou, Anastasia","Antonakos, Nikolaos","Damoraki, Georgia","Gkavogianni, Theologia","Adami, Maria-Evangelia","Katsaounou, Paraskevi","Ntaganou, Maria","Kyriakopoulou, Magdalini","Dimopoulos, George","Koutsodimitropoulos, Ioannis","Velissaris, Dimitrios","Koufargyris, Panagiotis","Karageorgos, Athanassios","Katrini, Konstantina","Lekakis, Vasileios","Lupse, Mihaela","Kotsaki, Antigone","Renieris, George","Theodoulou, Danai","Panou, Vassiliki","Koukaki, Evangelia","Koulouris, Nikolaos","Gogos, Charalambos","Koutsoukou, Antonia"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320677","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.chom.2020.04.009","keywords":["covid-19","hla-dr","sars-cov-2","dysregulation","ferritin","interleukin-6","lymphopenia","macrophage activation","monocytes","respiratory failure"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664815087841443840,"score":368.0021}]}